Richard J. Ablin

Corporate Officer/Principal bei Tetragenex Pharmaceuticals, Inc.

Consumer Services

Health Technology

Profil

Richard J.
Ablin is currently the Director of Tetracycline Evaluation at Tetragenex Pharmaceuticals, Inc. He was previously the Director and Research Associate Professor at The State University of New York from 1983 to 1989.
Ablin received his doctorate degree from the State University of New York at Buffalo in 1967.

Aktive Positionen von Richard J. Ablin

Unternehmen	Position	Beginn
Tetragenex Pharmaceuticals, Inc. Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY.	Corporate Officer/Principal	05.02.2010

Alle aktiven Positionen von Richard J. Ablin

Ehemalige bekannte Positionen von Richard J. Ablin

Unternehmen	Position	Ende
The State University of New York	Direktor/Vorstandsmitglied	01.01.1989

Sehen Sie sich die Erfahrung von Richard J. Ablin im Detail an

Ausbildung von Richard J. Ablin

State University of New York at Buffalo

Doctorate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Richard J. Ablin im Detail an

Beziehungen

100 +

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	1
Tetragenex Pharmaceuticals, Inc. Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY.	Health Technology